Bullish & Foolish
Full VVOS fundamentals All 466 on the Survival Watch

VVOSVivos Therapeutics, Inc.

Is Vivos Therapeutics struggling financially?

Yes, by its own account. Vivos Therapeutics told the SEC on 20 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

13/100

Critical

Sector
Biotech/Pharma
Market cap
$6.0M
Source filing
10-Q 20 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 2months

    If it eases off

    Empty by Aug 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$1.8M

÷

Cash burned over the last 12 months

$17.6M

What Vivos Therapeutics told the SEC

…objectives over the next twelve months from the date of the issuance of these financial statements. Without additional financing, these factors raise substantial doubt regarding the Company’s ability to continue as a going concern. We have implemented cost savings measures that lead to reduced impact to cash used in operations. However, sales did not grow in the financial year ended December 31, 2025 and the…

Vivos Therapeutics, Inc., Form 10-Q, filed 20 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 82.8% share-count increase The company issued stock. Each share now owns 45.3% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Operating earnings cover only -6.3x the interest bill, so the interest is being met out of cash reserves rather than out of the business.
  • Cash burn is narrowing It is spending 31% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt